Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
FDA Approves IMULDOSA® (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA
Accord BioPharma announces FDA approval of IMULDOSA, a biosimilar to STELARA for treating chronic inflammatory conditions. Anticipated launch in H1 2025, marking Accord's second biosimilar approval.
From Skepticism to Success: Insights Into Biosimilar Market Acceptance
Ivo Abraham discusses early biosimilar research challenges in the US, emphasizing the need for affordable drug strategies and volume contracts. He recalls initial skepticism and the shift towards equity in biosimilar development.
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
Dong-A ST received FDA approval for Imuldosa, a Stelara biosimilar, amidst a crowded market of approved but unlaunched biosimilars. Stelara's sales are expected to decline post-2023 patent expiry, with biosimilars like Amgen's Wezlana and Samsung Bioepis's Pyzchiva set to launch in 2025. Stelara, an IL-12/IL-23 inhibitor, treats psoriatic arthritis, Crohn’s disease, plaque psoriasis, and ulcerative colitis.
Related Clinical Trials:
Abbott advances two pulsed field ablation studies for AFib treatment
Abbott achieved milestones in two PFA trials for AF treatment, with the VOLT-AF study enrolling ahead of schedule and the FOCALFLEX study underway. The VOLT PFA system showed positive results in a feasibility study, and Abbott's Advisor HD Grid X Mapping Catheter received FDA clearance. PFA, using short bursts of electrical energy, is seen as an advancement over thermal ablation.
Abbott enrolls pivotal PFA study 4 months ahead of schedule
Abbott completed enrollment in a global clinical trial of its Volt pulsed field ablation (PFA) system four months ahead of schedule, aiming to compete with Boston Scientific and Medtronic. The trial's primary endpoint is the rate of freedom from atrial fibrillation after 12 months. Abbott also received clearance for its Advisor HD Grid X Mapping Catheter and initiated a Tactiflex Duo Ablation Catheter trial. Analysts view PFA devices as a threat to Abbott's electrophysiology business, but CEO Robert Ford anticipates market entry for Abbott's PFA portfolio next year.
Related Clinical Trials:
FDA Approves Imuldosa, a Fifth Biosimilar to Stelara
The FDA approved Imuldosa (ustekinumab-srlf), a biosimilar to Stelara, for treating autoimmune diseases. Stelara, a top-grossing biologic, generated $10.86 billion globally in 2023. Imuldosa is the fifth ustekinumab biosimilar approved in the US, developed by Dong-A ST and Meiji Seika Pharma, and will be commercialized by Intas Pharmaceuticals.
FDA Approves Imuldosa, a Biosimilar to Stelara
The FDA approved Imuldosa (ustekinumab-srlf), a biosimilar to Stelara, for treating plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. Stelara, a top-grossing biologic, generated $10.86 billion globally in 2023. Imuldosa is the fifth ustekinumab biosimilar approved by the FDA, developed by Dong-A ST and Meiji Seika Pharma, and will be commercialized by Intas Pharmaceuticals.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC
Apalutamide showed a 24-month overall survival benefit over enzalutamide in metastatic castration-sensitive prostate cancer patients, with a 23% reduced risk of death (HR, 0.77; 95% CI, 0.62-0.96; P = .019), consistent with the TITAN trial findings.
Sanofi may have found a buyer for its consumer health business
Sanofi in talks with Clayton Dubilier & Rice for sale of 50% stake in consumer health unit Opella, potentially worth €15 billion. Sale aims to focus resources on biopharmaceutical business, mirroring trends among big pharmas like Novartis, Pfizer, GSK, and Johnson & Johnson.
© Copyright 2025. All Rights Reserved by MedPath